Mar 05, 2014 8:05 am EST Heat Biologics, Inc. Appoints Taylor H. Schreiber, M.D., PH.D. as Vice President of Research and Development
Mar 03, 2014 8:05 am EST Heat Biologics Commences Dosing of First Patient in Phase 1/2 Study of Novel Cancer Immunotherapy Product Candidate HS-410 for the Treatment of Bladder Cancer
Feb 04, 2014 8:05 am EST Heat Biologics, Inc. to Present at 16th Annual BIO CEO & Investor Conference on Tuesday, February 11, 2014
Feb 03, 2014 8:35 am EST Heat Biologics, Inc. Announces Formation of Clinical Advisory Board With Preeminent Immunotherapy and Oncology Experts
Jan 17, 2014 8:05 am EST Heat Biologics, Inc. to Present at "TEN"; Noble Financial Capital Markets' Tenth Annual Equity Conference on Tuesday, January 21, 2014
Dec 30, 2013 1:15 pm EST Heat Biologics Announces Its Phase 1/2 Study of HS-410 in Bladder Cancer Is Open for Enrollment
Dec 17, 2013 8:00 am EST Heat Biologics, Inc. Appoints Dr. Anil K. Goyal as Vice President of Business Development
Dec 02, 2013 8:05 am EST Heat Biologics, Inc. to Present at 25th Annual Piper Jaffray Healthcare Conference
Nov 25, 2013 8:30 am EST Heat Biologics Successfully Completes Manufacturing of HS-410 to Start Phase 1/2 Bladder Cancer Trial